Oestrogen relaxes human epicardial coronary arteries through non-endothelium-dependent mechanisms. 1995

A H Chester, and C Jiang, and J A Borland, and M H Yacoub, and P Collins
Department of Cardiothoracic Surgery, National Heart and Lung Institute, Harefield Hospital, UK.

BACKGROUND Oestrogen-replacement therapy is associated with a reduced incidence of cardiovascular disease. The acute administration of oestrogen improves myocardial ischemia in women with coronary heart disease. In this study we investigated the relaxing effect of oestradiol-17 beta on human coronary arteries in vitro and determined the role of endothelial modulation in this relaxation by using isolated human coronary arteries. METHODS Atherosclerosis-free epicardial arteries from men and women were removed from patients undergoing heart or combined heart and lung transplantation. The arteries were cut into ring segments and placed into organ baths containing Tyrode's solution. Changes in isometric tension were measured. The relaxing response to oestradiol-17 beta (10(-10) - 10(-5) mol/l) was investigated and the effects of endothelium, NGmonomethyl-L-arginine and indomethacin on the response of oestradiol-17 beta were assessed. RESULTS Oestradiol-17 beta (10(-10) - 10(-5) mol/l) induced significant relaxation in coronary arteries pre-contracted with the thromboxane A2 analog (U46619; 3 x 10(-8) mol/l). Relaxation was significantly greater in coronary arteries from female patients. No significant differences were observed between arteries with or without endothelium nor after nitric oxide synthase or cyclo-oxygenase inhibition. These results indicate that oestradiol-17 beta induces human coronary artery relaxation via an endothelium-independent mechanism in vitro. The sex of the patients significantly affects sensitivity of the coronary arterial rings to oestrogen. CONCLUSIONS Oestradiol-17 beta-induced coronary relaxation may play an important role in regulation of coronary tone, and may partly explain why oestrogen improves myocardial ischemia in women and why it protects postmenopausal women from the risk of developing coronary heart disease.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011450 Prostaglandin Endoperoxides, Synthetic Synthetic compounds that are analogs of the naturally occurring prostaglandin endoperoxides and that mimic their pharmacologic and physiologic activities. They are usually more stable than the naturally occurring compounds. Prostaglandin Endoperoxide Analogs,Prostaglandin Endoperoxide Analogues,Synthetic Prostaglandin Endoperoxides,Analogues, Prostaglandin Endoperoxide,Endoperoxide Analogues, Prostaglandin,Endoperoxides, Synthetic Prostaglandin
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003331 Coronary Vessels The veins and arteries of the HEART. Coronary Arteries,Sinus Node Artery,Coronary Veins,Arteries, Coronary,Arteries, Sinus Node,Artery, Coronary,Artery, Sinus Node,Coronary Artery,Coronary Vein,Coronary Vessel,Sinus Node Arteries,Vein, Coronary,Veins, Coronary,Vessel, Coronary,Vessels, Coronary
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme

Related Publications

A H Chester, and C Jiang, and J A Borland, and M H Yacoub, and P Collins
December 2015, Biochemical and biophysical research communications,
A H Chester, and C Jiang, and J A Borland, and M H Yacoub, and P Collins
December 2015, British journal of pharmacology,
A H Chester, and C Jiang, and J A Borland, and M H Yacoub, and P Collins
June 2002, Biochemical and biophysical research communications,
A H Chester, and C Jiang, and J A Borland, and M H Yacoub, and P Collins
September 1986, European journal of pharmacology,
A H Chester, and C Jiang, and J A Borland, and M H Yacoub, and P Collins
December 1992, Circulation research,
A H Chester, and C Jiang, and J A Borland, and M H Yacoub, and P Collins
November 2000, The Journal of pharmacology and experimental therapeutics,
A H Chester, and C Jiang, and J A Borland, and M H Yacoub, and P Collins
November 1995, Circulation research,
A H Chester, and C Jiang, and J A Borland, and M H Yacoub, and P Collins
September 2003, Pharmacology,
A H Chester, and C Jiang, and J A Borland, and M H Yacoub, and P Collins
February 2000, Journal of cardiovascular pharmacology,
A H Chester, and C Jiang, and J A Borland, and M H Yacoub, and P Collins
February 1994, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!